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0883-9441/© 2017 Published by Elsevier Inc.a b s t r a c ta r t i c l e i n f oAvailable online xxxx Antibiotic therapy (AT) is the cornerstone of themanagement of severe community-acquired pneumonia (CAP).
However, the best treatment strategy is far from being established.
To evaluate the impact of different aspects of AT on the outcomeof critically ill patientswith CAP,weperformed a
post hoc analysis of all CAP patients enrolled in a prospective, observational, multicentre study.
Of the 502 patients included, 76% received combination therapy, mainly a β-lactam with a macrolide (80%). AT
was inappropriate in 16% of all microbiologically documented CAP (n= 177). Hospital and 6 months mortality
were 34% and 35%. In adjustedmultivariate logistic regression analysis, combination ATwith amacrolidewas in-
dependently associated with a reduction in hospital (OR 0.17, 95%CI 0.06–0.51) and 6 months (OR 0.21, 95%CI
0.07–0.57)mortality. Prolonged AT (N7 days)was associatedwith a longer ICU (14 vs. 7 days; p b 0.001) and hos-
pital length of stay (LOS) (25 vs. 17 days; p b 0.001).
Combination ATwith amacrolidemay be themost suitable AT strategy to improve both short and long term out-
come of severe CAP patients. AT N7 days had no survival benefit and was associated with a longer LOS.
© 2017 Published by Elsevier Inc.Keywords:
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Outcome1. Introduction
Community-acquired pneumonia (CAP), described in 1892 as the
“Captain of the men of Death” by Sir William Osler [1], represents a
major cause of morbidity, mortality and healthcare costs [2-4]. It re-
mains one of the leading causes of hospital admission and 5–15% of
the hospitalized patients will be admitted to an Intensive Care Unit
(ICU) [5], largely owing to complications such as shock or respiratory
failure.ia; CI, confidence interval; CT,
I, infection on admission to the
everity index; RCT, randomized
monia; SOFA, sequential organ
ive Care Department, Centro
ersity of Porto Medical School,
âni Monteiro, 4200-319 Porto,
.Severe community-acquired pneumonia (SCAP) is undoubtedly a
life threatening infectionwith amortality rate around30% [6]. Antibiotic
therapy is definitely the cornerstone of its treatment but the best antibi-
otic strategy has not been established yet. The combination of a
macrolide or a “respiratory” fluoroquinolone with a β-lactam, is advo-
cated by international guidelines [7-9]. Those who seem to benefit
most from this combination therapy are patients with bacteremic pneu-
mococcal pneumonia [10-12], septic shock [13] and invasive mechani-
cal ventilation [14]. However controversy persists since this
recommendation is supportedmostly by retrospective and observation-
al nonrandomized studies [10-12,15,16]. Furthermore, empiric use of
combination therapy to all patients with SCAP may lead to antibiotic
overuse and consequently to the emergence of antimicrobial resistance
in addition to increased risk for Clostridium difficile associated diarrhea
and adverse drug events.
The aim of this studywas to evaluate the impact of different features
of antibiotic therapy (timing, mono vs combination therapy, macrolide
use, appropriateness and duration) on short (hospital) and long term
(6 months) outcome of SCAP patients admitted to the ICU.
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2.1. Study design and data collection
The Infection on Admission to the ICU (INFAUCI) study was a pro-
spective, observational, cohort, multicentre study [17]. The study proto-
col was described elsewhere [17]. Briefly all adult patients (age
≥ 18 years) consecutively admitted during one year to one of the 14 Por-
tuguese participating units were included and followed until death or
6 months after ICU admission. The Hospital Research and Ethics Com-
mittee of CentroHospitalar S. João approved the study design. Infections
and sepsis criteriawere identified at the timeof admission to the ICU ac-
cording to commonly used definitions [18]. For the purpose of this
study, we analysed data from patients with SCAP at ICU admission.
CAP diagnosis was based on the presence of suggestive clinical features
(e.g. cough, fever, sputum production, pleuritic chest pain) and a de-
monstrable new infiltrate on chest radiograph or CT scan [19]. It was
classified as severe if it required ICU admission, mainly due to the
need of vasopressor support or invasivemechanical ventilation. Patients
with pulmonary tuberculosis (n = 7) or without available antibiotic
therapy data (n= 27) were excluded from the analysis.
Microbiologic evaluation was performed on a local basis and antibi-
otic therapywas prescribed according to the attending physician. Inmi-
crobiologically documented infections, antibiotic therapy was
considered appropriate if all isolated microorganisms had in vitroFig. 1. Flow-charsensitivity to at least one of the prescribed antimicrobials. Antibiotics
that Pseudomonas aeruginosa has not intrinsic resistance were classified
as antipseudomonal antibiotics.
Our primary outcome was short (hospital) and long term mortality
(6 months), both in the overall population and in the subset of patients
with septic shock. In addition,we also evaluated the impact of antibiotic
therapy in ICU and hospital length of stay (LOS). Six months mortality
was defined as death by any cause within this time frame counted
from ICU admission. LOS was calculated among patients alive at least
after 7 days of starting antibiotic therapy and was defined as the num-
ber of days from ICU admission to the date of either ICU or hospital
discharge.
2.2. Statistical analysis
Categorical variables were described as counts and percentages and
continuous variableswere expressed asmedian (percentile (P) 5 – P 95)
or mean ± standard deviation according to data distribution. Compari-
sons between groups were performed with the unpaired Student's t-
test, Mann–Whitney U test or Kruskal-Wallis for continuous variables
and Chi-square test and Fisher's exact test for categorical variables, as
appropriate.
The associations between antibiotic therapy and patient's outcome
were assessed by odds ratio (OR) with 95% confidence interval (CI) es-
timated by logistic regression, adjusted for all relevant variables.t of patients.
Table 2
Etiology of SCAP (n= 502 episodes).
Microrganisms n = (%)
Gram positive 79 (15.7)
Streptococcus pneumoniae 50 (10)
Staphylococcus aureus 28 (5.6)
Other Streptococcus spp. 1 (0.2)
Gram negative 78 (15.5)
Pseudomonas spp. 16 (3.2)
E. coli 15 (3.2)
Klebsiella spp. 12 (2.4)
Haemophilus influenza 12 (2.4)
Enterobacter spp. 7 (1.4)
Proteus spp. 4 (0.8)
Legionella pneumophila 3 (0.6)
Acinetobacter spp. 3 (0.6)
Serratia spp. 2 (0.4)
Moraxella catarrhalis 2 (0.4)
Other Gram negative 2 (0.4)
Virus 37 (7.4)
H1N1 36 (7.2)
Other virus 1 (0.2)
Other microrganisms 8 (1.6)
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NY, USA). All statistics were two-tailed and the significance level was
defined as p b 0.05.
3. Results
3.1. Patient characteristics
A total of 3766 consecutive patients were included in the INFAUCI
study. Infection on ICU admissionwas present in 44%, including 536 ad-
mitted with SCAP (14.2%). The final study population consisted of 502
patients with SCAP who had antibiotic therapy data available (Fig. 1).
Most of the patients (66%) were male with a mean age of 58 ±
17 years and a Simplified Acute Physiology Score II (SAPS II) score of
46 ± 18. On the day of ICU admission, the mean Sequential Organ Fail-
ure Assessment (SOFA) score and lactate were respectively 9 ± 4 and
3.0 ± 3.1 mmol/l. Mean ICU and hospital LOS were 14 ± 13 and 25 ±
22 days, respectively. Hospital and 6-months mortality were, respec-
tively, 34% and 35% (Table 1).
SCAP was microbiologically documented in 35% of the episodes (n
=177) with secondary bacteremia being present in 54 cases (11%). Al-
though Streptococcus pneumoniaewas the most frequent isolated path-
ogen (n=50; 10%), Gram negative bacteria were responsible for 15.5%
of the cases (n = 78). Viral pneumonia was documented in 7.4% (n =
37) (Table 2). Polymicrobial cases represented 11% of allmicrobiological
documented SCAP. Forty percent of the patients had some kind of im-
munosuppression. In 15% of them, co-infection of bacteria plus influen-
za virus was observed. Enterobacteriaceae (50%) and Staphylococcus
aureus (40%) were the most frequent pathogens isolated in
polymicrobial pneumonia.
3.2. Antibiotic treatment
Most of the patients (n=381; 76%) received combination antibiotic
therapy, mainly a β-lactam plus a macrolide (80%). In one third of theTable 1
Baseline characteristics (n= 502 patients).
n = 502
Age, mean (sd) 58 (17)
Male, n(%) 332 (66)
SAPS II, mean (sd) 46 (18)
Functional status, n(%)
Bedridden 11 (2)
Independent 448 (89)
Limited activity 43 (9)
Co-morbidity, n(%) 348 (70)
Alchoolism 73 (15)
Diabetes Mellitus 106 (21)
Chronic Hepatic Disease 33 (7)
Neurologic Disease 55 (11)
HIV/AIDS 22 (4)
Chronic Heart Failure 56 (11)
Imunossupression 41 (8)
Chronic Renal Failure 30 (6)
Chronic Respiratory Failure 90 (18)
Cancer 52 (10)
Drug Addiction 14 (3)
Total SOFA, mean (sd) 9 (4)
Septic Shock, n(%) 224 (45)
Lactate (mmol/l), mean (sd) 3.03 (3.07)
Microbiological documentation, n(%) 177 (35)
Monomicrobial, n(%) 157 (89)
Secondary bacteremia, n(%) 54 (11)
Length of stay, mean (sd)
ICU 14 (13)
Hospital 25 (22)
Mortality, n(%)
Hospital 172 (34)
6 Months 178 (35)patients, an antipseudomonal antibiotic was used. The empiric antimi-
crobial treatment was inappropriate in 16% of all microbiologically doc-
umented cases.
Data on timing to antibiotic first dose was only available in 174 pa-
tients (35%). 83% of the patients received the first dose in the first 6 h
after hospital admission but only 38% of patients received it within the
first hour (Table 3).
3.3. Antibiotic treatment and mortality
Although hospital mortality was similar in patients treated with an-
tibiotic monotherapy or with combination therapy (37% vs. 33%; p =
0.43), it was significantly lower when a combination therapy including
aβ-lactamand amacrolidewas used (27% vs. 58% for all other antibiotic
regimens; p b 0.001). Likewise, hospital mortality was also lower when
the initial empiric antibiotic regimenwas appropriate (30% vs. 56%; p=
0.01), but it was higher eitherwhen an antibioticwith antipseudomonal
activity was empirically used (48% vs. 28%; p b 0.001) or if timing to an-
tibiotic first dosewas ≤1 h (41% vs. 25%; p=0.03). No significant differ-
ence in hospital mortality was observed between patients that received
7 days or less of appropriate antibiotic therapy and those treated for a
longer period (23% vs. 28%; p = 0.39). Similar results were observed
when 6monthsmortality was used as outcome variable, instead of hos-
pital mortality (Table 3).
In a multivariate logistic regression analysis, age (OR 1.04; 95%CI
1.01–1.08), SOFA score (OR 1.26; 95%CI 1.05–1.50), inappropriate em-
piric antibiotic therapy (OR 6.83; 95%CI 1.43–32.57) and lactate on ad-
mission (OR 1.13; 95%CI 1.00–1.32) were all independently associated
with hospitalmortality. On the contrary, the use of combination therapy
including a macrolide proved to be protector (OR 0.19; 95%CI 0.06–
0.61). Age (OR 1.04; 95%CI 1.01–1.07) and SOFA score (OR 1.22; 95%CI
1.04–1.43) remained associatedwithmortality at 6monthswhilst com-
bination therapy including a macrolide persisted protective (OR 0.24;
95%CI 0.08–0.69) (Table 4). These results were not influenced by the
presence of any kind of immunodeficiency and its presence was not as-
sociatedwith both short (OR 1.76; 95%CI 0.61–5.04) and long termmor-
tality (OR 1.66; 95%CI 0.62–4.41) (data not shown).
3.4. Antibiotic treatment and length of stay
Combination therapywas associatedwith amarginally longermedi-
an ICU LOS than monotherapy [10 (P5–95: 2–40) vs. 9 (P5–95: 2–43)
days; p = 0.05] but no differences were found between the two groups
regarding hospital LOS [19 (P5–95: 3–70) vs. 18 (P5–95: 2–63) days; p
Table 3
Antibiotic strategies and Hospital and 6 months mortality.
Hospital mortality 6 Months mortality
Total Survivor Non-Survivor p= Total Survivor Non-Survivor p=
Antibiotic appropriateness
(n= 152)
0.01 0.03
Appropriate 127 (84) 89 (70) 38 (30) 127 (84) 85 (67) 42 (33)
Inappropriate 25 (16) 11 (44) 14 (56) 25 (16) 11 (44) 14 (56)
Number of antibiotics
(n = 502)
0.43 0.65
Monotherapy 121 (24) 76 (63) 45 (37) 121 (24) 76 (63) 45 (37)
Combination therapy 381 (76) 254 (67) 127 (33) 381 (76) 248 (65) 133 (35)
Combination of antibiotics
(n = 381)
b0.001 b0.001
With a Macrolide 305 222 (73) 83 (27) 305 217 (71) 88 (29)
Without a Macrolide 76 32 (42) 44 (58) 76 31 (41) 45 (59)
Anti-pseudomonal antibiotic
(n = 502)
b0.001 b0.001
Yes 161 (32) 84 (52) 77 (48) 161 (32) 82 (51) 79 (49)
No 341 (68) 246 (72) 95 (28) 341 (68) 242 (71) 99 (29)
Timing to antibiotic first dose
(n= 174)
0.03 0.04
≤ 1 h 66 (38) 39 (59) 27 (41) 66 (38) 39 (59) 27 (41)
N 1 h 108 (62) 81 (75) 27 (25) 108 (62) 80 (74) 28 (26)
Duration of adequate antibiotic therapy
(n= 339)
0.39 0.46
≤ 7 days 134 (40) 103 (77) 31 (23) 134 (40) 101 (75) 33 (25)
N 7 days 205 (60) 147 (72) 58 (28) 205 (60) 147 (72) 58 (28)
186 J.M. Pereira et al. / Journal of Critical Care 43 (2018) 183–189= 0.12]. Median ICU [10 (P5–95: 2–40) vs. 9 (P5–95: 2–29) days; p =
0.08] and hospital [20 (P5–95: 3–71) vs. 18 (P5–95: 2–65) days; p =
0.2] LOS were similar whether combination therapy included or not a
macrolide. Neither appropriate antibiotic therapy nor empiric use of
an antipseudomonal antibiotic had impact on ICU and hospital LOS. Pa-
tients that received antibiotic therapy for N7 days had a longer median
ICU [14 (P5–95: 3–48) vs. 7 (P5–95: 2–27) days; p b 0.001] and hospital
[25 (P5–95: 10–83) vs. 17 (P5–95: 6–59) days; p b 0.001] LOS. (Table 5).3.5. Antibiotic treatment and septic shock patients
Combination therapy by itself was again not associated with a sur-
vival benefit in the sub-group of septic shock patients (hospital mortal-
ity of 43% vs. 41%; p = 0.82). Nevertheless, when this combination
included a macrolide, hospital mortality was also significantly lower
(35% vs. 68%; p b 0.001). On the opposite, regimens that included an
antipseudomonal antibiotic were associated with higher hospital mor-
tality (63% vs. 32%; p b 0.001).Table 4
Logistic regression analysis for Hospital and 6 Months mortality (n= 115).
Hospital mortality 6 Months
mortality
OR 95%CI OR 95%CI
Age 1.04 1.01–1.08 1.04 1.01–1.07
Gender malea 0.27 0.09–0.83 0.45 0.16–1.27
Lactate 1.13 1.00–1.32 1.07 0.91–1.24
SOFA 1.26 1.06–1.50 1.22 1.04–1.43
Independentb 0.20 0.10–4.18 0.27 0.01–5.26
Limited activityb 0.14 0.01–4.22 0.27 0.01–7.48
Septic shockc 0.40 0.11–1.39 0.63 0.20–1.95
No co-morbiditiesd 0.64 0.18–2.29 0.99 0.32–3.09
Inappropriate antibiotic therapye 6.83 1.43–32.57 3.70 0.90–15.19
Combination therapy with macrolidef 0.19 0.06–0.61 0.24 0.08–0.69
a vs female.
b vs bedridden.
c vs. without septic shock.
d vs. presence of co-morbidities.
e vs appropriate antibiotic therapy.
f Combination therapy without macrolide.Antibiotic therapy was inappropriate in only 10% of septic shock pa-
tients. This was associated with a non-statistically significant higher
mortality (57% vs. 35%; p= 0.41). In 25% of these patients (n=20), an-
tibiotic therapy was started within 1 h after hospital admission and this
was associatedwith higher hospitalmortality (60% vs. 28%; p=0.02). A
longer course of antibiotic therapy (N7 days) provided no survival ben-
efit (Table 6). The effect of these antibiotic strategies on mortality
persisted after 6 months (Table 6).
In a logistic regression analysis, combination therapy with a
macrolide was the only independently variable that proved to be pro-
tective against both hospital (OR 0.09; 95%CI 0.02–0.52) and 6 months
mortality (OR 0.16; 95%CI 0.03–0.75) in SCAP patients with septic
shock. Lactate on admissionwas independently associatedwith hospital
mortality (OR 1.11; 95%CI 1.00–1.37), but not with 6 months mortality,
in this subset of patients (Table 7).
4. Discussion
The main findings of this study are the following: 1) Globally, com-
bination therapy did not improve survival in this cohort of critically ill
patients; 2) However, combination therapy with a macrolide was inde-
pendently associated with a lower hospital and 6 months mortality,
namely in patients with septic shock; 3) Inappropriate empiric antibiot-
ic therapy was independently associated with hospital mortality in the
overall population, but this association was not observed in the subset
of patients with septic shock on admission to the ICU; 4) Duration of ap-
propriate antibiotic therapy not longer than 7 days was not associated
with aworst outcome nor increased ICU or hospital LOS; 5) Lactate con-
centration on ICU admissionwas an independent risk factor for hospital
mortality.
One of the controversial issues in antibiotic therapy for SCAP is the
potential advantage of combination therapy. Data to support the recom-
mendation of international guidelines to use combination therapy is
coming mainly from non-randomized and retrospective studies [7,8]
and randomized controlled trials (RCTs) are lacking.
Recently, Gattarello et al. observed a significant increase in ICU sur-
vival when combination antibiotic therapy was used, both in pneumo-
coccal (OR 0.19; 95% CI: 0.07–0.51) [20] and in non-pneumococcal
SCAP (OR 0.23; 95%CI 0.07–0.74) [21]. On the opposite, in a large RCT
of CAP patients this benefit was not observed, even in the most severe
Table 5
Antibiotic strategies and ICU and Hospital LOS.
ICU Length of Stay Hospital Length of Stay
n= Median P05-P95 p= n= Median P05-P95 p=
Appropriateness 0.87 0.46
Appropriate 126 10 2–40 121 22 2–87
Inappropriate 25 11 2–33 25 20 3–57
Number of antibiotics 0.05 0.12
Monotherapy 118 9 2–43 117 18 2–63
Combination therapy 376 10 2–40 368 19 3–70
Combination of antibiotics 0.08 0.20
With a Macrolide 74 9 2–40 73 18 2–63
Without a Macrolide 302 10 2–38 295 20 3–71
Anti-pseudomonal antibiotic 0.18 0.82
No 337 10 2–40 331 19 3–72
Yes 157 9 2–38 154 20 2–63
Timing to antibiotic first dose 0.20 0.03
≤ 1 h 65 9 2–37 65 14 2–53
N 1 h 104 10 1–38 101 18 3–73
Duration of adequate antibiotic therapy b0.001 b0.001
≤ 7 days 133 7 2–27 130 17 6–59
N 7 days 204 14 3–48 199 25 10–83
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mitted to the ICU [22].
Similarly, no difference in 60-day mortality was also found by Adrie
et al. between patients receiving dual and monotherapy (Hazards Ratio
1.14; 95% CI: 0.86–1.50; p=0.37), even when the analysis was restrict-
ed to pneumococcal pneumonia, to microbiologically documented CAP
or to patients with septic shock [23]. Likewise, we did not find a clear
mortality benefit of combination therapy as a whole in our cohort.
Whether the administration of a specific antibiotic combination is
associated with a better outcome in SCAP patients is still not clear. De-
spite the fact that a benefit from combination therapy is mostly seen
when macrolides are part of the antibiotic regimen [13,14], those stud-
ies are mostly observational and retrospective and no firm recommen-
dation is given in international guidelines [7,8].
New data has recently been published regarding this issue. A large
systematic review and meta-analysis of almost 10,000 critically ill pa-
tients with SCAP revealed that macrolide combination therapy was as-
sociated with a marginally significant lower mortality compared with
non-macrolide therapies (21% vs 23%; Relative Risk 0.84 95%CI 0.71–
1.00) [24]. However, when the same analysis was restricted to prospec-
tive studies or to patients with either septic shock or invasive mechan-
ical ventilation, no benefit was found. In another observational study of
pneumococcal CAP, the authors reported a non-significant decrease in
mortality in SCAP cases when a β-lactam plus macrolide combinationTable 6
Antibiotic strategies in septic shock patients and mortality.
Hospital mortality
Survivor Non-sur
Appropriateness (n= 73)
Appropriate 43 (65) 23 (35)
Inappropriate 3 (43) 4 (57)
Number of antibiotics (n= 224)
Monotherapy 26 (59) 18 (41)
Combination therapy 103 (57) 77 (43)
Combination of antibiotics (n= 180)
With a Macrolide 90 (65) 49 (35)
Without a Macrolide 13 (32) 28 (68)
Anti-pseudomonal antibiotic (n = 224)
Yes 28 (37) 48 (63)
No 101 (68) 47 (32)
Timing to antibiotic first dose (n= 80)
≤ 1 h 8 (40) 12 (60)
N 1 h 43 (72) 17 (28)
Duration of adequate antibiotic therapy (n= 127)
≤ 7 days 29 (67) 14 (33)
N 7 days 62 (74) 22 (26)was used (Hazards Ratio 0.67; 95% CI 0.37–1.25) [25]. More recently,
no significant differences in mortality were observed between a β-lac-
tam-macrolide and a β-lactam-quinolone regimen in ICU patients
with non-pneumococcal SCAP [21]. The benefit of combination antibiot-
ic therapy may be more consistent in the more severe sub-group of pa-
tients, as proposed by Rodriguez et al. [13], who found, in another
observational study, that in CAP patients the benefit of combination
therapy was restricted to septic shock patients (Hazards Ratio for
monotherapy 2.69; 95%CI 1.09–2.6). This was consistent with findings
in another large cohort of septic shock patients where the early use of
combination antibiotic therapy, namely a β-lactam in combination
with an aminoglycoside, a fluoroquinolone or amacrolide, was associat-
ed with improved survival [26].
In our study, the use of a combination antibiotic therapy that includ-
ed a macrolide was independently associated with a significant reduc-
tion in hospital (OR 0.19; 95%CI 0.06–0.61) and 6 months (OR 0.24;
95%CI 0.08–0.69)mortality. The same benefit was notedwhen the anal-
ysis was restricted to the specific cohort of patients with septic shock.
Inadequate empirical antibiotic treatment was independently asso-
ciated with hospital mortality in septic patients admitted to the ICU
with “nonsurgical” sepsis (OR 8.14; 95%CI 1.98–33.5) [27] and a fivefold
reduction in survival (OR 8.99; 95% CI: 6.60–12.23) in septic shock pa-
tients [28]. Regarding SCAP, few studies specifically evaluated the im-
pact of antibiotic inappropriateness. Falagas et al., in a systematic6 months mortality
vivor p= Survivor Non-survivor p=
0.41 0.44
40 (61) 26 (39)
3 (43) 4 (57)
0.82 0.62
26 (59) 18 (41)
99 (55) 81 (45)
b0.001 0.001
86 (62) 53 (38)
13 (32) 28 (68)
b0.001 b0.001
27 (36) 49 (64)
98 (66) 50 (34)
0.02 0.02
8 (40) 12 (60)
42 (70) 18 (30)
0.45 0.32
27 (63) 16 (37)
60 (71) 24 (29)
Table 7
Logistic regression analysis for hospital and 6 months mortality in septic shock
patients (n = 61).
Hospital mortality 6 months mortality
OR 95%CI OR 95%CI
Age 1.02 0.97–1.07 1.02 0.98–1.06
Gender malea 0.44 0.08–2.49 1.03 0.22–4.88
Lactate 1.11 1.00–1.37 1.03 0.85–1.25
SOFA 1.22 0.94–1.57 1.22 0.96–1.55
No co-morbiditiesb 0.26 0.02–2.92 1.33 0.24–7.49
Inappropriate antibiotic therapyc 4.20 0.33–53.48 1.44 0.17–12.12
Combination therapy with macrolided 0.09 0.02–0.52 0.16 0.03–0.75
a vs female.
b vs. Presence of co-morbidities.
c vs appropriate antibiotic therapy.
d vs. combination therapy without macrolide.
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pneumonia, did not observe a statistically significant difference in mor-
tality (19 vs. 21%; p=0.66) or clinical success (88 vs. 83%; p=0.57) be-
tween appropriate and inappropriate antibiotic [29]. Similar results
were noted in a prospective, observational study of 844 patients with
pneumococcal bacteremia, a high mortality rate irrespective of the ap-
propriateness of antibiotic therapy [10]. On the opposite, a recent
multicentre observational cohort French study suggested that initial ad-
equate antibiotic therapywas associatedwith a better survival (Hazards
Ratio 0.63; 95% CI: 0.42–0.94) in SCAP patients, namely in patients with
septic shock [23]. However, in this study, initial antibiotic therapy was
considered adequate if at least one antibiotic was active in vitro against
the isolated pathogen or, in the non-microbiologically documented
SCAP, if treatment was in accordance with current guidelines, although
this can bemisleading. In our study, despite the low rate ofmicrobiolog-
ical documentation, there was an association between initial appropri-
ate antibiotic therapy and survival. Yet, in our logistic regression
model, this association was only verified with hospital but not with
long term mortality. In the subgroup of patients with septic shock, we
did not identify association between inappropriate initial antibiotic
therapy with either short or long term mortality (Tables 4 and 7).
According to international guidelines [7,8], an antipseudomonal an-
tibiotic should be prescribed whenever risk factors for Pseudomonas
aeruginosa are present. Interestingly, we observed significantly higher
hospital mortality in those patients that received an antipseudomonal
antibiotic.We can hypothesize that this could have resulted fromhigher
toxicity, worse coverage of grampositive bacteriawith some drugs (e.g.,
ceftazidime) and higher rate of nosocomial infections caused by multi-
drug resistant microorganisms. Another possible explanation is the
use by the attending physician of broad spectrum antibiotics with
anti-pseudomonal activity in the most severe cases of CAP which can
be associated with a higher mortality. These results raise the question
onwhichpatients shouldwe empirically treatwith anantipseudomonal
antibiotic. Patientswith structural lung abnormalities (e.g., bronchiecta-
sis), severe chronic obstructive pulmonary disease, immunosuppressed
and those previous colonized with Pseudomonas aeruginosa are those
who probably will benefit from the empiric use of antipseudomonal
drug but this needs to be confirmed in future studies.
In a responding patient, both European [8] and American [7] guide-
lines recommend that treatment duration should generally not exceed
7–8 days, although there are no RCT to support it in SCAP. Indeed little
is known about the impact of shortened treatments in critically ill pa-
tients. After excluding patients that died in the first 7 days after ICU ad-
mission, we found that receiving 7 days or less of adequate antibiotic
treatment did not led to higher short or long term mortality rate but
was associated with a slightly shorter ICU and hospital LOS. Our data
are consistent with other published studies. Recently, Uranga et al.
[30], in amulticentre RCT, including 39% of patients with SCAP (PSI clas-
ses IV-V), showed that shorter duration of therapy (median 5 days) wasnot associated with higher in-hospital mortality or longer hospital LOS.
The same was noted by Choudhury et al. [31], in a prospective observa-
tional study of SCAP patients (CURB score 3–5): no difference in 30-day
mortality between short (7 days) or longer (N7 days) antibiotic regi-
mens. However patients admitted to the ICU were excluded in both
studies.
Serum lactate is a well-known prognostic marker in septic patients.
It has been associated with short term mortality in severe septic pa-
tients independently of organ dysfunction or shock [32]. In CAP its prog-
nostic role is not well documented. Gwak et al. observed that in
hospitalized CAP patients, including 18% admitted to the ICU, initial
serum lactate concentrationwas independently associatedwith in-hos-
pital mortality (aOR1.24; 95%CI 1.01–1.53) [33]. In our specific cohort of
SCAP patients, initial serum lactatewas associatedwith hospitalmortal-
ity (OR 1.13; 95%CI 1.00–1.32), namely in patientswith septic shock (OR
1.11; 95%CI 1.00–1.37), but not with long term mortality.
Some strengths of our study deserve to be highlighted: the large
number of critically ill patients with SCAP (almost half with septic
shock) prospectively included and the different aspects of antibiotic
therapy that were simultaneously addressed.
However, several limitations also merit consideration. Firstly, and
most importantly, this was an observational study and unknown bias
may have influenced the results. Secondly, we did not use any pneumo-
nia specific score to assess severity, although these scores have been
shown to be more useful to identify low-risk patients that can be safely
discharged. We also did not collect data regarding the use of adjuvant
therapies, namely corticosteroids, which could impact on outcome.
Lack of data regarding intubation rate and duration of mechanical ven-
tilation are also limitations that should be stated. Nevertheless, mean
respiratory SOFA score on ICU admission was 3, showing that a large
proportion of patients received invasivemechanical ventilation. Bacteri-
al load and the virulence of the microorganisms were other variables
that were not collected and could have impacted outcome.
5. Conclusions
In SCAP patients, the only antibiotic strategy that seems to improve
significantly both hospital and 6 months mortality is the use of combi-
nation of antibiotics that includes a macrolide. Appropriate empiric an-
tibiotic therapy improved short term survival (but not in the subgroup
of patients with septic shock). Courses of appropriate antibiotic therapy
longer than 7 days are not associated with a survival benefit but may
lead to longer ICU and hospital LOS. Serum lactate showed to be a
good prognostic marker of hospital mortality.
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